Ciphergen Biosystems Receives Notice of Intent from U.S. Patent Office for Re-Issuance of SELDI Mass Spectrometry Patent
July 11 2007 - 9:00AM
PR Newswire (US)
Bio-Rad Laboratories to Pay $2 Million Upon Issuance of Patent
Reexamination Certificate FREMONT, Calif., July 11
/PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH)
today announced that the company received from the United States
Patent and Trademark Office a notice of intent to issue a
Reexamination Certificate of U.S. patent no. 6,734,022, which is
directed to a fundamental process of SELDI mass spectrometry. Upon
reissuance of the patent, Bio-Rad Laboratories is to pay Ciphergen
$2.0 million pursuant to the terms of the Asset Purchase Agreement
entered into in connection with the sale of Ciphergen's
instrumentation business to Bio-Rad on November 13, 2006. "We are
pleased that the USPTO has decided to re-issue this patent as we
believe it further validates the innovation underlying SELDI
technology," said Gail S. Page, Ciphergen President and Chief
Executive Officer. About Ciphergen Ciphergen Biosystems, Inc. is
dedicated to the discovery, development and commercialization of
novel high-value diagnostic tests that help physicians diagnose,
treat and improve outcomes for patients. Ciphergen, along with its
scientific collaborators, has ongoing diagnostic programs in
oncology/hematology, cardiology and women's health with an initial
focus in ovarian cancer. Ciphergen is based in Fremont, California.
More information about Ciphergen can be found on the Web at
http://www.ciphergen.com/. Safe Harbor Statement This news release
contains forward-looking statements that involve significant risks
and uncertainties, including those that can be found in Ciphergen's
Form 10-K for the year ended December 31, 2006, and in Ciphergen's
periodic reports on Form 10-Q and Form 8-K. Statements in this
release are based upon information available to Ciphergen as of the
date of the release. Information and announcements involving
Ciphergen's expectations, beliefs, hopes, plans, intentions or
strategies regarding the future are forward-looking statements for
purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. We claim the protection of such safe
harbor, and disclaim any intent or obligation to update any
forward-looking statement contained in this document as a result of
new information, future events or otherwise. These statements are
not guarantees of future performance and actual results could
differ materially from our current expectations. NOTE: Ciphergen is
a registered trademark of Ciphergen Biosystems, Inc. DATASOURCE:
Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor
Relations of Ciphergen Biosystems, Inc., +1-510-505-2233; or Lori
Murray of WeissComm Partners, +1-415-946-1070, for Ciphergen
Biosystems, Inc. Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024